Origin House Announces Record Quarterly Revenue of $21.4 million for the Second Quarter of 2019; Sequential Growth of 91% from Q1 2019
Press Release
Ottawa, Canada – August 28, 2019 - CannaRoyalty Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) (“Origin House” or the “Company”), a North American cannabis products and brands company today announced its financial results for the three and six-month periods ended June 30, 2019. All figures are reported in Canadian dollars ($), unless otherwise indicated. Origin House’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).
For a more comprehensive overview of the Corporate and Financial highlights presented in this press release, please refer to Origin House’s Management Discussion and Analysis of the Financial Condition and Results of Operations for the three and six months ended June 30, 2019, and the Company’s Condensed Interim Consolidated Financial Statements for the three and six months ended June 30, 2019, which will be filed on SEDAR by August 29, 2019.
Corporate Highlights for the second quarter ended June 30, 2019
- Entered into a definitive agreement to be acquired by Cresco Labs for approximately $1.1 billion, forming one of the largest vertically integrated multi-state cannabis operators in the U.S.;
- Closed the acquisition of Cub City LLC (“Cub City”), adding expertise in the production of bespoke, exotic cannabis and a team that has produced for some of the top craft flower brands in California;
- Doubled FloraCal’s cultivation capacity in Sonoma County, California. Cultivation of ultra-premium cannabis began in the newly expanded space in July 2019;
- Began to distribute Cresco-branded products through Continuum in June 2019.
Corporate Highlights subsequent to the quarter ended June 30, 2019
- Entered into a binding term sheet agreement with Opaskwayak Cree Nation (“OCN”) for C$12 million in debt financing;
- The Company’s subsidiary Trichome Financial (“Trichome”) and 22 Capital Corp. (“22 Capital”) announced the unanimous approval from their respective shareholders for their amalgamation that will result in a reverse take-over of 22 Capital by the shareholders of Trichome; and
- Closed the sale of its equity interest in Alternative Medical Enterprises LLC (“AltMed”) for proceeds of US$6.0 million. The divestment of AltMed marks the completion of a key step toward the closing of the Company’s Arrangement with Cresco Labs.
Management Commentary
Marc Lustig, Chairman and CEO of Origin House commented, “I am very proud of the entire Origin House team for generating another quarter of record revenue growth, leveraging the California brand support and distribution platform we built over the past several years, to deliver results for shareholders. It speaks to the strength and maturity of our organization that we were able to increase our share of shelf in California while preparing to integrate with Cresco Labs. To that end, in this quarter, we successfully executed on the sale of Alternative Medical Enterprises LLC generating a 156% return on investment, our distribution division Continuum entered into a distribution agreement with Cresco and began distributing Cresco branded products across California, and we have made substantial progress on post-closing groundwork.”
Mr. Lustig continued, “In California, we have built a foundation that is capable of supporting a much larger business and expect to begin to drive significant operating leverage as we continue to grow revenue. With additional regulatory pressure on the illegal market in California, we expect 2020 to be a big year in the state. I am as confident as ever that the combination of Cresco Labs’ scale, expertise and brand portfolio with Origin House’s proven track record of leveraging our California-wide distribution footprint, is the best way for shareholders to participate in this growth. Together, we will be well-positioned to build a national, and one day, global house of brands.”
Update on Acquisition by Cresco Labs
As per the previously announced plan of arrangement pursuant to which Cresco Labs Inc. (“Cresco Labs”) will acquire all of the issued and outstanding shares of Origin House (the “Arrangement”). As recently disclosed, in connection with the antitrust review by the United States Department of Justice Antitrust Division (the “DOJ”) pursuant to the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, the Company and Cresco Labs received requests for additional information (“Second Requests”) from the DOJ. Both companies are in active discussions with the DOJ regarding the Second Requests and are confident that the Arrangement will be completed as planned.
Update on California Licensure
The Company also announced that its California distribution division, Continuum, has received a provisional state distribution license for its West Sacramento location from the California Bureau of Cannabis Control. This is the third such license issued to Continuum, and the ninth annual or provisional license received by an Origin House subsidiary. It also marks the completion of Origin House’s previously announced transition from temporary licensure to annual and provisional state licenses, which last a full year from issuance.
Financial Highlights for the second quarter ended June 30, 2019
The following are financial highlights of Origin House’s operating results for the three months ended June 30, 2019, compared to the three months ended June 30, 2018:
- Revenue was $21.4 million as compared to $3.5 million;
- Gross margin including gains on biological assets was $4.4 million as compared to $0.8 million;
- Operating expenses were $23.5 million as compared to $6.3 million;
- Loss from operations was $19.0 million as compared to $5.5 million;
- Net loss, driven by non-operating charges, was $34.9 million as compared to net income of $9.3 million;
- Adjusted EBITDA loss was $21.0 million as compared to Adjusted EBITDA income of $11.1 million.
The following non-operating factors increased the Company’s Q2 net loss:
- In connection with the Arrangement with Cresco Labs, $2.1 million in transaction costs were expensed as part of Selling, General and Administrative Expenses under Operating costs.
- Two non-cash, balance sheet adjustments arising out of the terms of the Arrangement with Cresco Labs (i.e. (i) the Sale of AltMed; (ii) the acceleration of the 180 Smoke acquisition contingent consideration) totaling $13.4 million were recorded as part of Other expenses.
The following is a summary of key balance sheet items as at June 30, 2019, compared to December 31, 2018:
- Cash and cash equivalents were $14.8 million as compared to $69.2 million;
- Total assets of $258.8 million as compared to $230.7 million;
- Current assets of $57.0 million as compared to $86.0 million;
- Current liabilities of $62.8 million as compared to $26.2 million; and
- Long-term debt financing of nil as compared to $16.0 million.
Results of Operations (Summary)
The following tables set forth consolidated statements of financial information for the three and six-month periods ended June 30, 2019 and June 30, 2018. For further information regarding the Company’s financial results for these periods, please refer to the Company’s Management’s Discussion and Analysis for the periods ended June 30, 2019 and June 30, 2018 and the Company’s Financial Statements for the periods ended June 30, 2019, which will be published on Origin House’s issuer profile on SEDAR at www.sedar.com and the Company’s website at www.OriginHouse.com, by August 29, 2019.
IBF4
